BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Metra M, Carubelli V, Ravera A, Stewart Coats AJ. Heart failure 2016: still more questions than answers. Int J Cardiol 2017;227:766-77. [PMID: 27838123 DOI: 10.1016/j.ijcard.2016.10.060] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 He L, Ma S, Zuo Q, Zhang G, Wang Z, Zhang T, Zhai J, Guo Y. An Effective Sodium-Dependent Glucose Transporter 2 Inhibition, Canagliflozin, Prevents Development of Hypertensive Heart Failure in Dahl Salt-Sensitive Rats. Front Pharmacol 2022;13:856386. [PMID: 35370704 DOI: 10.3389/fphar.2022.856386] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Chen S, Zhou Y, Wu X, Shi S, Wu H, Li P, Khalaf OI. The Value of Echocardiography Combined with NT-pro BNP Level in Assessment and Prognosis of Diastolic Heart Failure. Computational and Mathematical Methods in Medicine 2022;2022:1-8. [DOI: 10.1155/2022/2102496] [Reference Citation Analysis]
3 Grandinetti V, Carlos FP, Antonio EL, de Oliveira HA, Dos Santos LFN, Yoshizaki A, Mansano BSDM, Silva FA, Porte LA, Albuquerque-Pontes GM, de Carvalho PTC, Manchini MT, Leal-Junior EC, Tucci PJF, Serra AJ. Photobiomodulation therapy combined with carvedilol attenuates post-infarction heart failure by suppressing excessive inflammation and oxidative stress in rats. Sci Rep 2019;9:9425. [PMID: 31263132 DOI: 10.1038/s41598-019-46021-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
4 Kim YG, Han SJ, Kim DJ, Lee KW, Kim HJ. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study. Cardiovasc Diabetol 2018;17:91. [PMID: 29935543 DOI: 10.1186/s12933-018-0737-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 6.8] [Reference Citation Analysis]
5 Mishra S, Mohan JC, Nair T, Chopra VK, Harikrishnan S, Guha S, Ramakrishnan S, Ray S, Sethi R, Samal UC, Sarat Chandra K, Hiremath MS, Banerjee AK, Kumar S, Das MK, Deb PK, Bahl VK. Management protocols for chronic heart failure in India. Indian Heart J 2018;70:105-27. [PMID: 29455764 DOI: 10.1016/j.ihj.2017.11.015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
6 Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZI. Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials. Circulation 2017;136:1643-58. [PMID: 29061576 DOI: 10.1161/CIRCULATIONAHA.117.030012] [Cited by in Crossref: 205] [Cited by in F6Publishing: 220] [Article Influence: 41.0] [Reference Citation Analysis]
7 Santas E, de la Espriella-Juan R, Mollar A, Valero E, Miñana G, Sanchis J, Chorro FJ, Núñez J. Echocardiographic pulmonary artery pressure estimation and heart failure rehospitalization burden in patients with acute heart failure. Int J Cardiol 2017;241:407-10. [PMID: 28455131 DOI: 10.1016/j.ijcard.2017.04.055] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]